Venture Life Group PLC
LSE:VLG
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBITDA
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBITDA (EV/EBITDA) ratio compares a company`s total enterprise value to its earnings before interest, taxes, depreciation, and amortization. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBITDA returns to its 3-Year Average (7.9), the stock would be worth GBX59.24 (5% downside from current price).
| Scenario | EV/EBITDA Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 8.4 | GBX62.5 |
0%
|
| 3-Year Average | 7.9 | GBX59.24 |
-5%
|
| 5-Year Average | 8.5 | GBX63.34 |
+1%
|
| Industry Average | 0 | GBX0.18 |
-100%
|
| Country Average | 0 | GBX0.15 |
-100%
|
Forward EV/EBITDA
Today’s price vs future ebitda
| Today's Enterprise Value | EBITDA | Forward EV/EBITDA | ||
|---|---|---|---|---|
|
GBX47.9m
|
/ |
Jan 2026
£5.6m
|
= |
|
|
GBX47.9m
|
/ |
Jun 2026
£8.2m
|
= |
|
|
GBX47.9m
|
/ |
Jun 2027
£9.2m
|
= |
|
|
GBX47.9m
|
/ |
Jun 2028
£10.7m
|
= |
|
Forward EV/EBITDA shows whether today’s EV/EBITDA still looks high or low once future ebitda are taken into account.
Peer Comparison
| Market Cap | EV/EBITDA | P/E | ||||
|---|---|---|---|---|---|---|
| UK |
|
Venture Life Group PLC
LSE:VLG
|
80.5m GBP | 8.4 | 13.1 | |
| FR |
|
L'Oreal SA
PAR:OR
|
201.5B EUR | 18.7 | 32.9 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
93.4B GBP | 11.4 | 11.3 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.6T INR | 36.2 | 37.6 | |
| UK |
|
HALEON PLC
LSE:HLN
|
31.6B GBP | 13.3 | 19 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
28.1B USD | 14.6 | -158.1 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
15.8B EUR | 7.9 | 16.8 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 9.8 | 22.2 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.2T INR | 38.6 | 64.1 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | -6 373.4 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
815.9B INR | 31.5 | 43.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 0 |
| Median | 0 |
| 70th Percentile | 0 |
| Max | 743.2 |
Other Multiples
Venture Life Group PLC
Glance View
Venture Life Group Plc engages in the development, manufacture, and commercializing of products for the aging population. The company is headquartered in Bracknell, Berkshire and currently employs 119 full-time employees. The company went IPO on 2014-03-28. The firm is focused on developing, manufacturing and commercializing products for the global self-care market. The firm's segments include Brands, which includes sales of healthcare and skin care products under distribution agreements and direct to United Kingdom retailers, and Development and Manufacturing. Through its two Development and Manufacturing operations in Italy and Sweden, the Company also provides development and manufacturing services to companies in the medical devices and cosmetic sectors. Its product portfolio includes the UltraDEX and Dentyl oral care product ranges, the Balance Active range in the area of women's intimate healthcare, the Lift and Glucogel product ranges for hypoglycaemia, Gelclair and Pomi-T for oncology support, products for fungal infections and proctology, and dermo-cosmetics for addressing the signs of ageing.
